INVO Bioscience Says It Works Toward Stated Goal Of Reaching Break-Even Or Profitability Within Its Current Operations (Excluding Potential Merger With Naya) In 2024; Says Remain On Track To Reach That Objective
Author: Benzinga Newsdesk | April 16, 2024 05:08pm